学术论文

      乳腺癌组织中 CC 类趋化因子5和重组人 S100钙结合蛋白 A4表达与临床病理特征及预后的关系

      Expression of CCL5 and S100A4 protein in breast cancer tissues and their relationship with clinicopathological features and prognosis

      摘要:
      目的:探讨乳腺癌组织中 CC 类趋化因子5(CCL5)和重组人 S100钙结合蛋白 A4(S100A4)表达与临床病理特征及预后的关系。方法利用免疫组化法检测40例正常乳腺组织和120例乳腺癌组织中CCL5和 S100A4的表达程度,并分析表达程度与乳腺癌临床病理特征和预后的关系。结果乳腺癌组织中CCL5、S100A4表达阳性率分别为56.67%、62.50%,正常乳腺组织不表达,差异均有统计学意义(χ2CCL5=39.403,P <0.01;χ2S100A4=47.062,P <0.01);CCL5在乳腺癌组织中的表达与临床分期(χ2=10.141,P <0.01)、病理类型(χ2=5.769,P =0.017)、淋巴结是否转移(χ2=34.178,P <0.01),差异均有统计学意义,而与患者年龄、肿瘤大小、病理分级差异均无统计学意义(均 P >0.05);S100A4表达与患者临床分期(χ2=44.311,P <0.01)和淋巴结是否转移(χ2=14.843,P <0.01)差异均有统计学意义,与病理类型、年龄、肿瘤大小、病理分级差异均无统计学意义(均 P >0.05);乳腺癌组织中 CCL5、S100A4表达呈正相关(r =0.301,P <0.01);CCL5与乳腺癌复发呈正相关(OR =6.270,P <0.01),S100A4与乳腺癌复发无相关性(OR =1.103, P =0.768);生存分析表明,CCL5表达阳性的患者无瘤生存时间显著短于 CCL5表达阴性的患者(χ2=11.851,P <0.01),S100A4表达阳性的患者无瘤生存时间显著短于 S100A4表达阴性的患者(χ2=5.433,P =0.021);联合检测显示,CCL5阳性+S100A4阳性组无瘤生存时间显著短于 CCL5阳性或 S100A4阳性组(χ2=15.341,P <0.01)和 CCL5阴性+S100A4阴性组(χ2=15.341,P <0.01)。结论 CCL5和 S100A4在乳腺癌组织中的表达能够反映出癌组织转移、分期等情况,可用于乳腺癌临床病理特征和预后的判断。
      Abstract:
      Objective To investigate the relationship between the expression of CC chemokine ligand 5(CCL5)and S100 calcium binding protein A4 (S100A4)protein in breast cancer tissues with clinicopathological features and prognosis.Methods The expression of CCL5 and S100A4 in 40 cases of normal breast tissues and 120 cases of breast cancer were detected by immunohistochemistry,and the relationship between the degree of expres-sion and the clinicopathological features and prognosis of breast cancer was analyzed.Results The expression posi-tive rates of CCL5 and S100A4 in breast cancer tissues were 56.67% and 62.50% respectively,which were not expressed in normal breast tissues,and the differences were statistically significant (χ2CCL5 =39.403,P <0.01;χ2S100A4 =47.062,P <0.01).The expression of CCL5 in breast cancer tissues was statistically correlated with clinical staging(χ2 =10.141,P <0.01 ),pathological type (χ2 =5.769,P =0.017)and lymph node metastasis (χ2 =34.178,P <0.01),but not correlated with patients'age,tumor size,pathological grading(all P >0.05 ).And the expression of S100A4 was statistically correlated with clinical staging(χ2 =44.311,P <0.01)and lymph node metas-tasis(χ2 =14.843,P <0.01 ),but not correlated with patients'age,tumor size,pathological type and pathological grading(all P >0.05).The expression of CCL5 and S100A4 in breast cancer was positively correlated(r =0.301, P <0.01).CCL5 was positively correlated with the recurrence of breast cancer(OR =6.270,P <0.01),and S100A4 was not correlated with the recurrence of breast cancer(OR =1.103,P =0.768).Survival analysis showed that the disease -free survival time of patients with positive CCL5 expression was significantly shorter than the patients with negative CCL5 expression(χ2 =11.851,P <0.01 ),and the disease -free survival time of patients with positive S100A4 expression was significantly shorter than the patients with negative S100A4 expression(χ2 =5.433,P =0.021).The joint detection showed that the disease -free survival time in CCL5(+)+S100A4(+)group was sig-nificantly lower than that of CCL5(+)or S100A4(+)group(χ2 =15.341,P <0.01)and CCL5 (-)+S100A4 (-)group(χ2 =15.341,P <0.01).Conclusion The expression of CCL5 and S100A4 in breast cancer can reflect the metastasis and staging of breast cancer,which can be used to judge the clinical pathological characteristics and prognosis of breast cancer.
      Author: Lin Ya Zhang Jie Lin Yi Wu Qingqing
      作者单位: 温岭市第一人民医院病理科, 浙江省温岭,317500
      刊 名: 中国基层医药 ISTIC
      年,卷(期): 2017, 24(6)
      在线出版日期: 2017年3月29日